Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

IBIS-II investigators

doi:10.1016/S0140-6736(13)62292-8

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

IBIS-II investigators

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

483 Citations (Scopus)

446 Downloads (Pure)

Abstract

Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease.

Original language	English
Pages (from-to)	1041-8
Number of pages	8
Journal	Lancet
Volume	383
DOIs	https://doi.org/10.1016/S0140-6736(13)62292-8
Publication status	Published - 22 Mar 2014

Keywords

Adult
Aged
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Carcinoma, Lobular
Double-Blind Method
Female
Humans
Longitudinal Studies
Middle Aged
Nitriles
Postmenopause
Proportional Hazards Models
Risk Factors
Treatment Outcome
Triazoles

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(13)62292-8Licence: CC BY

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II)
Copyright 2013 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 453 KBLicence: CC BY

Stuart McIntosh
- s.mcintoshqub.acuk
- School of Medicine, Dentistry and Biomedical Sciences - Clinical Professor
- Patrick G Johnston Centre for Cancer Research
Person: Academic

Cite this

@article{acbe177b911b47d8af49b92738cfb45b,

title = "Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial",

abstract = "Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease.",

keywords = "Adult, Aged, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular, Double-Blind Method, Female, Humans, Longitudinal Studies, Middle Aged, Nitriles, Postmenopause, Proportional Hazards Models, Risk Factors, Treatment Outcome, Triazoles",

author = "Jack Cuzick and Ivana Sestak and Forbes, {John F} and Mitch Dowsett and Jill Knox and Simon Cawthorn and Christobel Saunders and Nicola Roche and Mansel, {Robert E} and {von Minckwitz}, Gunter and Bernardo Bonanni and Tiina Palva and Anthony Howell and {IBIS-II investigators} and Stuart McIntosh",

year = "2014",

month = mar,

day = "22",

doi = "10.1016/S0140-6736(13)62292-8",

language = "English",

volume = "383",

pages = "1041--8",

journal = "Lancet",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

AU - Cuzick, Jack

AU - Sestak, Ivana

AU - Forbes, John F

AU - Dowsett, Mitch

AU - Knox, Jill

AU - Cawthorn, Simon

AU - Saunders, Christobel

AU - Roche, Nicola

AU - Mansel, Robert E

AU - von Minckwitz, Gunter

AU - Bonanni, Bernardo

AU - Palva, Tiina

AU - Howell, Anthony

AU - IBIS-II investigators

AU - McIntosh, Stuart

PY - 2014/3/22

Y1 - 2014/3/22

N2 - Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease.

AB - Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease.

KW - Adult

KW - Aged

KW - Antineoplastic Agents, Hormonal

KW - Aromatase Inhibitors

KW - Breast Neoplasms

KW - Carcinoma, Ductal, Breast

KW - Carcinoma, Intraductal, Noninfiltrating

KW - Carcinoma, Lobular

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Longitudinal Studies

KW - Middle Aged

KW - Nitriles

KW - Postmenopause

KW - Proportional Hazards Models

KW - Risk Factors

KW - Treatment Outcome

KW - Triazoles

U2 - 10.1016/S0140-6736(13)62292-8

DO - 10.1016/S0140-6736(13)62292-8

M3 - Article

C2 - 24333009

VL - 383

SP - 1041

EP - 1048

JO - Lancet

JF - Lancet

ER -

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Profiles

Stuart McIntosh

Cite this